Dazl | $10,000,000 | (Sep 9, 2025)
Supersonik | $5,000,000 | (Sep 9, 2025)
Astradyne | $2,351,350 | (Sep 9, 2025)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
BoobyBiome | $3,391,787 | (Sep 9, 2025)
Atolio | $24,000,000 | (Sep 9, 2025)
Elysian | $6,000,000 | (Sep 9, 2025)
SCOREalytics, Inc. | $3,000,000 | (Sep 9, 2025)
florrent | $9,500,000 | (Sep 9, 2025)
Geniez AI | $6,000,000 | (Sep 9, 2025)
Maeving | $14,925,474 | (Sep 9, 2025)
ProRata.ai | $40,000,000 | (Sep 9, 2025)
ACT-ion | $4,000,000 | (Sep 9, 2025)